Arteriovenous fistulas and grafts for hemodialysis access experience high rates of dysfunction. The recent IN.PACT AV Access trial evaluated the safety and clinical benefit of the IN.PACT AV drug-coated balloon (DCB) compared to percutaneous transluminal angioplasty (PTA) for treatment of obstructive lesions of native arteriovenous fistulas. Our objective was to assess the budget impact of using DCB versus standard PTA in the German and U.S. healthcare systems, based on 12-month data from the IN.PACT AV Access trial.
